Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Rule 8.3 - Cyprotex PLC

DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE

(Rule 8.3 of the City Code on Takeovers and Mergers)

1. KEY INFORMATION

Name of person dealing (Note 1)                    MR G L A DOW

Company dealt in                                          CYPROTEX

Class of relevant security to which the
dealings being disclosed relate (Note 2)          ORDINARY SHARES

Date of dealing                                             12TH MARCH 2010

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

                                                                         Long                       Short
                                                                         Number       (%)        Number (%)

(1) Relevant securities                                        10,740,727    6.0%

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total                                                                   10,740,727    6.0%

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:                                      Long                   Short
                                                                           Number     (%)      Number (%)

(1) Relevant securities

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

(c) Rights to subscribe (Note 3)

Class of relevant security:                                     Details

3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale             Number of securities             Price per unit (Note 5)

PURCHASE                   500,000                                3.75P

(b) Derivatives transactions (other than options)

Product name            Long/short          Number of securities      Price per unit
e.g. CFD                    (Note 6)              (Note 7)                        (Note 5)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates(Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note5)

(ii) Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

(d) Other dealings (including new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                 YES/NO

Date of disclosure                                                        16TH MARCH 2010

Contact name                                                              G L A DOW

Telephone number                                                       022 6005856

If a connected EFM, name of offeree/offeror with which connected

If a connected EFM, state nature of connection (Note 10)

Notes

The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close